Skip to main content

Table 2 Overall survival in NEC cohort and invasive mammary carcinoma cohort according to clinical stage (2003–2009)

From: Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database

Cohort n Median survival in months (IQR) 5-year OS rate (95% CI) P
All     <0.0001
NEC 135 26 (12–48) 53.6 (42.2-63.7)  
IMC 374,598 34 (16–56) 79.8 (79.6-79.9)  
Stage I     0.002
NEC 32 33 (17–51) 74.4 (43.4-90.0)  
IMC 170,778 36 (18–58) 89.6 (89.2-89.6)  
Stage II     <0.0001
NEC 49 30 (19–52) 73.9 (56.3-85.3)  
IMC 123,430 36 (17–58) 82.4 (82.1-82.7)  
Stage III     0.014
NEC 16 19 (13–41) 58.2 (21.0-82.8)  
IMC 41,422 29 (14–48) 72.4 (71.8-73.1)  
Stage IV     NS
NEC 32 12 (4–25) 20.7 (5.70-42.1)  
IMC 17,830 15 (5–30) 27.9 (26.9-29.0)  
  1. Data from the Surveillance, Epidemiology and End Results Program, 2003 to 2009. NEC, neuroendocrine carcinoma; IMC, invasive mammary carcinoma; IQR, interquartile range; OS, overall survival; n, number of cases; HR, hazard ratio; CI, confidence interval; NS, not significant.